XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
As the options for systemic treatment of malignant melanoma (MM) increase, the need to develop biomarkers to identify patients who might benefit from cytotoxic chemotherapy becomes more apparent. In preclinical models, oxaliplatin has activity in cisplatin-resistant cells. In this study, we have sho...
Main Authors: | Hatch, S, Swift, L, Caporali, S, Carter, R, Hill, E, Macgregor, T, D'Atri, S, Middleton, M, McHugh, P, Sharma, R |
---|---|
פורמט: | Journal article |
יצא לאור: |
2014
|
פריטים דומים
-
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
מאת: Hatch, S, et al.
יצא לאור: (2014) -
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
מאת: MacGregor, T, et al.
יצא לאור: (2018) -
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
מאת: T. P. MacGregor, et al.
יצא לאור: (2018-05-01) -
Use of DNA repair proteins translated from biomarker screening to predict overall survival in patients with esophageal cancer treated with oxaliplatin chemotherapy
מאת: Sharma, R, et al.
יצא לאור: (2012) -
Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
מאת: Gillies, R, et al.
יצא לאור: (2011)